Local biotech firm raises $36M in round led by Philips, UPMC

ALung Technologies Inc., a Pittsburgh-based developer of an artificial lung device, has closed on $36 million in a Series C financing round led by Philips and UPMC, its largest capital raise to date. The money will support a U.S.-based pivotal trial for Food and Drug Administration approval of ALung’s Hemolung Respiratory Assist System. Both UPMC, which invested through its innovation and commercialization arm UPMC Enterprises, and Philips will offer resources and expertise to support ALung ’s…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news

Related Links:

Publication date: October 2018Source: The Annals of Thoracic Surgery, Volume 106, Issue 4Author(s): Branden W. Luna, Luca Paoletti, Chadrick E. Denlinger, Nicholas J. Pastis, Timothy P. WhelanAirway complications after lung transplantation are well described and can lead to significant morbidity and mortality. Treatment options for anastomotic dehiscence include expectant management, placement of endobronchial stents, or surgical repair. The use of fibrin sealant instilled by bronchoscopy to seal a dehiscence has not been well described. Our patient is a 57-year-old man who underwent orthotropic bilateral lung tr...
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
AbstractPurpose of ReviewConnective tissue disease-related interstitial lung disease (CTD-ILD) previously was a relative contraindication to lung transplantation primarily due to extra-pulmonary involvement of the disease. Recent published information focusing on the diagnosis and management of the extra-pulmonary complexities associated with CTD-ILD that challenge the success of lung transplantation indicate similar outcomes when compared to idiopathic causes of interstitial lung disease. Recent literature examining appropriate wait-listing criteria, disease management, and outcomes after lung transplantation are discusse...
Source: Current Respiratory Care Reports - Category: Respiratory Medicine Source Type: research
In a tale of two studies, it appears artificial intelligence is helping researchers analyze cells in ways that weren't possible before. In one study, published this week in Nature Methods, scientists at the Allen Institute in Seattle, WA used machine learning to train computers to see parts of the cell that the human eye cannot easily distinguish. Using 3D images of fluorescently labeled cells, the team taught computers to find structures inside living cells without fluorescent labels, using only black and white images generated by an inexpensive technique known as brightfield microscopy. Fluorescence microscop...
Source: MDDI - Category: Medical Devices Authors: Tags: Imaging Source Type: news
Almost exactly a year ago, Tiffany and Chuck Palmer were told to expect a stillborn baby. Now, their son is eight months, after getting both his heart and lungs replaced. And he is home in Kansas City.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Physicians may soon use artificial intelligence (AI) and medical images to study tumors without a biopsy. The techniques developed to study tumors in this new way are described in the September 1 issue of The Lancet Oncology. Along with helping physicians learn more about tumors without surgery, the new approach should help identify which cancer patients will respond best to cutting-edge immunotherapy treatments. The AI techniques could be useful for “predicting clinical outcomes of patients treated with immunotherapy when validated by further prospective randomized trials,” the authors wrote. Immunotherapy tre...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Infection with the hepatitis C virus (HCV) has adverse liver, kidney, and cardiovascular consequences in patients with chronic kidney disease (CKD), including those on dialysis therapy and in those with a kidney transplant. Since the publication of the original Kidney Disease: Improving Global Outcomes (KDIGO) HCV Guideline in 2008, major advances in HCV management, particularly with the advent of direct-acting antiviral therapies, have now made the cure of HCV possible in CKD patients. In addition, diagnostic techniques have evolved to enable the noninvasive diagnosis of liver fibrosis.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Guideline Summary Source Type: research
XACT Robotics has received CE mark for its robotics navigation steering system. On top of that, the Caesarea, Israel-based company has raised about $5 million in a series C round. How’s that for being efficient? The company said the funds will mainly be used for the launch and operation of seven Centers of Excellence in the US, Europe, and Israel, where the company expects that hundreds of clinical procedures will be conducted within the next 12 months with the XACT robotic navigation and steering system. The XACT robotics system is currently approved and being used for CT-guided percutaneous procedures i...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news
American Journal of Transplantation,Volume 0, Issue ja, -Not available-.
Source: American Journal of Transplantation - Category: Transplant Surgery Authors: Source Type: research
AbstractThe lung allocation score system in the United States and several European countries gives more weight to risk of death without transplantation than to survival following transplantation. As a result, centers transplant sicker patients, leading to increased length of initial hospitalization. The care of patients who have accumulated functional deficits or additional organ dysfunction during their prolonged stay can be ethically complex. Disagreement occurs between the transplant team, patients and families, and non-transplant health care professionals over the burdens of ongoing intensive intervention. These cases ...
Source: HEC Forum - Category: Medical Ethics Source Type: research
ConclusionThe GLCCI1 variant was associated with a significant decrease of the TLC at 3  years after LT and the development of CLAD at 3 years, especially in patients undergoing cadaveric LT.
Source: Surgery Today - Category: Surgery Source Type: research
More News: Biotechnology | Food and Drug Administration (FDA) | Health Management | Lung Transplant | Respiratory Medicine